https://scholars.lib.ntu.edu.tw/handle/123456789/473644
標題: | IGF2BP3 (IMP3) expression is a marker of unfavorable prognosis in ovarian carcinoma of clear cell subtype | 作者: | Köbel M. Xu H. Bourne P.A. Spaulding B.O. Shih I.-M. TSUI-LIEN MAO Soslow R.A. Ewanowich C.A. Kalloger S.E. Mehl E. Lee C.-H. Huntsman D. Gilks C.B. |
關鍵字: | Cancer; IGF2BP3; Immunohistochemistry; IMP3; Ovarian clear cell carcinoma; Prognosis | 公開日期: | 2009 | 卷: | 22 | 期: | 3 | 起(迄)頁: | 469-475 | 來源出版物: | Modern Pathology | 摘要: | Clear cell carcinoma is an uncommon subtype of ovarian carcinoma, accounting for 10% of cases. Clear cell carcinoma typically presents with stage I or II disease, and in this setting prognostic markers could aid in management decisions, in particular the decision to treat with adjuvant chemotherapy. We tested whether expression of insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3, also known as IMP3) can serve as a new biomarker to predict outcome for patients with clear cell carcinoma and other subtypes of ovarian carcinoma. The expression of IGF2BP3 was evaluated by immunohistochemistry in 475 ovarian carcinomas of different subtypes and correlated with disease-specific survival. IGF2BP3 antibody specificity was validated by correlation of IGF2BP3 protein with mRNA expression level in a series of 35 ovarian carcinomas (r=0.849, P<0.0001). IGF2BP3 protein expression was an independent marker of reduced disease-specific survival (risk ratio 2.9, 95% confidence interval 1.4-5.8) in the clear cell subtype (N=128), but not in high-grade serous (N=198) or endometrioid (N=121) carcinomas. The prognostic significance of IGF2BP3 expression for reduced disease-specific survival (risk ratio 2.6, 95% confidence interval 1.3-5.0) was confirmed in an independent series of cases (N=150) from three different centers in North America. We conclude that IGF2BP3 is the first biomarker of prognostic significance in ovarian clear cell carcinoma that has been validated in an independent case series. ? 2009 USCAP, Inc All rights reserved. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-61349152949&doi=10.1038%2fmodpathol.2008.206&partnerID=40&md5=c9ca44bb9eb95127012d1bb000921982 https://scholars.lib.ntu.edu.tw/handle/123456789/473644 |
ISSN: | 0893-3952 | DOI: | 10.1038/modpathol.2008.206 | SDG/關鍵字: | biological marker; protein igf2bp3; somatomedin B; unclassified drug; article; human; immunohistochemistry; major clinical study; North America; ovarian clear cell carcinoma; ovary carcinoma; priority journal; protein expression; tissue microarray; Adenocarcinoma, Clear Cell; Female; Gene Expression; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Middle Aged; Neoplasm Proteins; Ovarian Neoplasms; Prognosis; RNA, Messenger; RNA-Binding Proteins; Tissue Array Analysis; Tumor Markers, Biological |
顯示於: | 病理學科所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。